Cargando…
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
BRAF(V600E)-mutant malignant melanomas depend on RAF/MEK/ERK (MAPK) signaling for tumor cell growth(1). RAF and MEK inhibitors show remarkable clinical efficacy in BRAF(V600E) melanoma(2, 3); however, resistance to these agents remains a formidable challenge(2, 4). Global characterization of resista...
Autores principales: | Johannessen, Cory M., Johnson, Laura A., Piccioni, Federica, Townes, Aisha, Frederick, Dennie T., Donahue, Melanie K., Narayan, Rajiv, Flaherty, Keith T., Wargo, Jennifer A., Root, David E., Garraway, Levi A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4098832/ https://www.ncbi.nlm.nih.gov/pubmed/24185007 http://dx.doi.org/10.1038/nature12688 |
Ejemplares similares
-
The melanocyte lineage in development and disease
por: Mort, Richard L., et al.
Publicado: (2015) -
Lineage Relationship of Direct-Developing Melanocytes and Melanocyte Stem Cells in the Zebrafish
por: Tryon, Robert C., et al.
Publicado: (2011) -
Overexpression of Mcl-1 confers resistance to BRAF(V600E) inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
por: Fofaria, Neel M., et al.
Publicado: (2015) -
Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013) -
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition
por: Young, Helen L., et al.
Publicado: (2017)